MedPath

Staphylococcus aureus toxoid multivalent vaccine (Integrated BioTherapeutics)

Generic Name
Staphylococcus aureus toxoid multivalent vaccine (Integrated BioTherapeutics)

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Jun 17, 2025

LBT-SA7 (IBT-V02): A Rationally Designed Toxoid Vaccine Poised to Overcome Decades of Failure in the Staphylococcus aureus Field

Executive Summary

The landscape of Staphylococcus aureus vaccine development is a veritable graveyard of promising candidates, marked by decades of high-profile and costly clinical failures. LBT-SA7, a multivalent toxoid vaccine originally developed by Integrated BioTherapeutics (IBT) as IBT-V02 and now advanced by LimmaTech Biologics, represents a significant paradigm shift in this challenging field. This report posits that LBT-SA7 is built upon a scientifically rational and strategically de-risked foundation that directly addresses the fundamental flaws of its predecessors. By targeting key secreted toxins rather than bacterial surface antigens, the vaccine is engineered to neutralize the pathogen’s primary virulence and immune-evasion mechanisms, an approach strongly supported by extensive preclinical data and a growing understanding of S. aureus immunopathology.

The core innovation of LBT-SA7 lies in its mechanism. Historical attempts to develop an S. aureus vaccine have focused on generating opsonizing antibodies against surface antigens, a strategy that has not only failed to confer protection but has, in some cases, been associated with deleterious immune responses and increased mortality in vaccinated individuals who subsequently became infected.[1] LBT-SA7 circumvents this issue by targeting a cocktail of six rationally designed, detoxified proteins (toxoids) that neutralize the pathogen’s pore-forming toxins and superantigens.[5] This approach is designed to disarm the bacterium, protecting host tissues and preserving the integrity of the immune system, thereby allowing for effective clearance.

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.